Ascendis Pharma As Stock Today
| ASND Stock | USD 140.89 1.28 0.90% |
Performance4 of 100
| Odds Of DistressLess than 26
|
Ascendis Pharma is trading at 140.89 as of the 18th of April 2024, a -0.9 percent decrease since the beginning of the trading day. The stock's lowest day price was 140.23. Ascendis Pharma has about a 26 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Ascendis Pharma AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of October 2023 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of January 2015 | Category Healthcare | Classification Health Care |
Ascendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Ascendis Pharma is traded on NASDAQ Exchange in the United States. The company has 56.61 M outstanding shares of which 3.35 M shares are presently shorted by private and institutional investors with about 10.88 trading days to cover. More on Ascendis Pharma AS
Moving together with Ascendis Stock
| 0.62 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.72 | JSPRW | Jasper Therapeutics | PairCorr |
Ascendis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Ascendis Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Ascendis Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Jan Mikkelsen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Ascendis Pharma report their recommendations after researching Ascendis Pharma's financial statements, talking to executives and customers, or listening in on Ascendis Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Ascendis Pharma AS. The Ascendis consensus assessment is calculated by taking the average forecast from all of the analysts covering Ascendis Pharma. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Ascendis Pharma's financial statements, Ascendis Pharma AS may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Ascendis Pharma AS is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ascendis Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Ascendis Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ascendis Pharma's financial leverage. It provides some insight into what part of Ascendis Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ascendis Pharma AS (ASND) is traded on NASDAQ Exchange in USA. It is located in Tuborg Boulevard 12, Hellerup, Denmark, 2900 and employs 879 people. Ascendis Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.01 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ascendis Pharma's market, we take the total number of its shares issued and multiply it by Ascendis Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ascendis Pharma AS conducts business under Biotechnology sector and is part of Health Care industry. The entity has 56.61 M outstanding shares of which 3.35 M shares are presently shorted by private and institutional investors with about 10.88 trading days to cover.
Ascendis Pharma AS currently holds about 955.15 M in cash with (467.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11.
Check Ascendis Pharma Probability Of Bankruptcy
Ownership AllocationAscendis Pharma AS retains a total of 56.61 Million outstanding shares. The majority of Ascendis Pharma AS outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Ascendis Pharma AS to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Ascendis Pharma. Please pay attention to any change in the institutional holdings of Ascendis Pharma AS as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Ascendis Ownership Details
Ascendis Stock Price Odds Analysis
What are Ascendis Pharma's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Ascendis Pharma jumping above the current price in 90 days from now is about 70.84%. The Ascendis Pharma AS probability density function shows the probability of Ascendis Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Ascendis Pharma has a beta of 0.9992. This suggests Ascendis Pharma AS market returns are highly-sensitive to returns on the market. As the market goes up or down, Ascendis Pharma is expected to follow. Additionally, ascendis Pharma AS has an alpha of 0.0916, implying that it can generate a 0.0916 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Ascendis Pharma to move above the current price in 90 days from now is about 70.84 (This Ascendis Pharma AS probability density function shows the probability of Ascendis Stock to fall within a particular range of prices over 90 days) .
Ascendis Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Ascendis Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ascendis Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ascendis Pharma's value.| Instituion | Recorded On | Shares | |
| Franklin Resources Inc | 2023-12-31 | 1.1 M | |
| Amvescap Plc. | 2023-12-31 | 907.9 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 845.7 K | |
| Timessquare Capital Management, Llc | 2023-12-31 | 792.9 K | |
| Sofinnova Ventures | 2023-12-31 | 754 K | |
| Putnam Investments Llc | 2023-12-31 | 725.7 K | |
| Vestal Point Capital Lp | 2023-12-31 | 625 K | |
| Alliancebernstein L.p. | 2023-12-31 | 588.9 K | |
| Spyglass Capital Management Llc | 2023-12-31 | 539.9 K | |
| Ra Capital Management, Llc | 2023-12-31 | 10.1 M | |
| Artisan Partners Limited Partnership | 2023-12-31 | 5.7 M |
Ascendis Pharma Historical Income Statement
Ascendis Pharma AS Income Statement is one of the three primary financial statements used for reporting Ascendis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Ascendis Pharma AS revenue and expense. Ascendis Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Ascendis Pharma's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 277.6 M, whereas EBIT is projected to grow to (434.2 M). View More FundamentalsAscendis Stock Against Markets
Picking the right benchmark for Ascendis Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Ascendis Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Ascendis Pharma is critical whether you are bullish or bearish towards Ascendis Pharma AS at a given time. Please also check how Ascendis Pharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ascendis Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Ascendis Pharma Corporate Directors
Ascendis Pharma corporate directors refer to members of an Ascendis Pharma board of directors. The board of directors generally takes responsibility for the Ascendis Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Ascendis Pharma's board members must vote for the resolution. The Ascendis Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Jonathan Silverstein | Director | Profile | |
| Edwin Graaf | Director | Profile | |
| Michael Mayer | Director | Profile | |
| Rafaele Tordjman | Director | Profile |
How to buy Ascendis Stock?
Before investing in Ascendis Pharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Ascendis Pharma. To buy Ascendis Pharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Ascendis Pharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Ascendis Pharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Ascendis Pharma AS stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Ascendis Pharma AS stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Ascendis Pharma AS, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Ascendis Stock please use our How to Invest in Ascendis Pharma guide.
Already Invested in Ascendis Pharma AS?
The danger of trading Ascendis Pharma AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ascendis Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ascendis Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ascendis Pharma AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Ascendis Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.10) | Revenue Per Share 4.739 | Quarterly Revenue Growth 5.014 | Return On Assets (0.30) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.